Filing Flows › 4D Molecular Therapeutics (FDMT) › Next earnings date
4D Molecular Therapeutics (FDMT) earnings on Nov 10, 2026: what to expect
4D Molecular Therapeutics (FDMT) is expected to report earnings on Nov 10, 2026 (estimated), in 2 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$1.05 (−$1.10 to −$0.99, 11 estimates) on revenue of $3.1M, against −$1.01 and $90K a year ago. It beat the EPS estimate in 25% of the quarters on record; Filing Flows' model gives it a 53% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$1.01 on revenue of $231K, against the analysts' −$1.05.
The last report
4D Molecular Therapeutics reported revenue of $3.8M for the second quarter 2026 (252× Y/Y), net loss $72.9M. How it makes money → · Every quarter →
4D Molecular Therapeutics' latest quarter
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart follows the revenue to costs, profit and cash.
Questions
When does FDMT report earnings?
4D Molecular Therapeutics is expected to report on Nov 10, 2026 (estimated).
What are analysts expecting from 4D Molecular Therapeutics?
EPS of −$1.05 and revenue of $3.1M for the quarter.
Does 4D Molecular Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 25% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.